Osimertinib was administered for 6 months until the serum concentration of three tumor biomarkers reached normal limits (CA19-9: 249 U/mL, CA-125: 60.1 U/mL; CEA: 15.1 ng/mL). Here, MUC16 is linked to neoplasm.